Tasmar®

In November 1998, FDA and Hoffmann-La Roche Inc., the manufacturer of the drug Tasmar® for patients with Parkinson's Disease, advised doctors about reports of fatal liver injury associated with use of the drug, and recommended significant changes in how it is used. Because of these reports, Tasmar®'s labeling now states that the drug should be reserved for use only in patients who do not have severe movement abnormalities and who don't respond to or who are not appropriate candidates for other available treatments.

About 60,000 patients have been given Tasmar® worldwide, indicating a rate of approximately one reported death for every 20,000 patients using the drug. FDA and Hoffmann-La Roche are asking health professionals to exercise additional caution in using the product and to report any additional cases of liver injury.

Source: fda.gov

If you or a loved one has been harmed by Tasmar®, you may want to contact a Tasmar® attorney for more information.